vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and Ladder Capital Corp (LADR). Click either name above to swap in a different company.
Ladder Capital Corp is the larger business by last-quarter revenue ($22.3M vs $16.1M, roughly 1.4× Journey Medical Corp). Ladder Capital Corp runs the higher net margin — 71.0% vs -7.8%, a 78.8% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs -18.0%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs -22.5%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Ladder Capital Corp is a leading commercial real estate finance firm operating primarily across the United States. It originates and manages a diversified portfolio of senior secured commercial mortgage loans, mezzanine debt, commercial mortgage-backed securities, and direct real estate assets, serving property owners, operators and developers across major market segments.
DERM vs LADR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $22.3M |
| Net Profit | $-1.2M | $15.9M |
| Gross Margin | — | — |
| Operating Margin | -2.8% | 69.5% |
| Net Margin | -7.8% | 71.0% |
| Revenue YoY | 27.3% | -18.0% |
| Net Profit YoY | -182.0% | -49.4% |
| EPS (diluted) | $-0.04 | $0.13 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $22.3M | ||
| Q3 25 | $17.0M | $27.8M | ||
| Q2 25 | $15.0M | $21.5M | ||
| Q1 25 | $13.1M | $20.3M | ||
| Q4 24 | $12.6M | $27.2M | ||
| Q3 24 | $14.6M | $38.4M | ||
| Q2 24 | $14.9M | $34.3M | ||
| Q1 24 | $13.0M | $37.1M |
| Q4 25 | $-1.2M | $15.9M | ||
| Q3 25 | $-2.3M | $19.2M | ||
| Q2 25 | $-3.8M | $17.1M | ||
| Q1 25 | $-4.1M | $11.6M | ||
| Q4 24 | $1.5M | $31.3M | ||
| Q3 24 | $-2.4M | $27.6M | ||
| Q2 24 | $-3.4M | $32.1M | ||
| Q1 24 | $-10.4M | $16.4M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 82.3% | — | ||
| Q3 24 | 63.9% | — | ||
| Q2 24 | 56.0% | — | ||
| Q1 24 | 47.7% | — |
| Q4 25 | -2.8% | 69.5% | ||
| Q3 25 | -9.0% | 72.4% | ||
| Q2 25 | -19.2% | 96.7% | ||
| Q1 25 | -25.3% | 52.7% | ||
| Q4 24 | 17.7% | — | ||
| Q3 24 | -19.8% | 74.1% | ||
| Q2 24 | -19.7% | 90.4% | ||
| Q1 24 | -77.4% | 49.4% |
| Q4 25 | -7.8% | 71.0% | ||
| Q3 25 | -13.6% | 69.0% | ||
| Q2 25 | -25.3% | 79.5% | ||
| Q1 25 | -31.0% | 56.8% | ||
| Q4 24 | 12.1% | 115.1% | ||
| Q3 24 | -16.3% | 71.7% | ||
| Q2 24 | -22.6% | 93.6% | ||
| Q1 24 | -80.1% | 44.2% |
| Q4 25 | $-0.04 | $0.13 | ||
| Q3 25 | $-0.09 | $0.15 | ||
| Q2 25 | $-0.16 | $0.14 | ||
| Q1 25 | $-0.18 | $0.09 | ||
| Q4 24 | $0.10 | $0.25 | ||
| Q3 24 | $-0.12 | $0.22 | ||
| Q2 24 | $-0.17 | $0.26 | ||
| Q1 24 | $-0.53 | $0.13 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $38.0M |
| Total DebtLower is stronger | $25.3M | — |
| Stockholders' EquityBook value | $31.9M | $1.5B |
| Total Assets | $94.6M | $5.2B |
| Debt / EquityLower = less leverage | 0.79× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $38.0M | ||
| Q3 25 | $24.9M | $49.4M | ||
| Q2 25 | $20.3M | $134.9M | ||
| Q1 25 | $21.1M | $479.8M | ||
| Q4 24 | $20.3M | $1.3B | ||
| Q3 24 | $22.5M | $1.6B | ||
| Q2 24 | $23.9M | $1.2B | ||
| Q1 24 | $24.1M | $1.2B |
| Q4 25 | $25.3M | — | ||
| Q3 25 | $25.2M | — | ||
| Q2 25 | $25.1M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $24.9M | — | ||
| Q3 24 | $19.8M | — | ||
| Q2 24 | $19.7M | — | ||
| Q1 24 | $14.7M | — |
| Q4 25 | $31.9M | $1.5B | ||
| Q3 25 | $25.9M | $1.5B | ||
| Q2 25 | $19.2M | $1.5B | ||
| Q1 25 | $21.5M | $1.5B | ||
| Q4 24 | $20.1M | $1.5B | ||
| Q3 24 | $10.9M | $1.5B | ||
| Q2 24 | $11.3M | $1.5B | ||
| Q1 24 | $13.0M | $1.5B |
| Q4 25 | $94.6M | $5.2B | ||
| Q3 25 | $85.2M | $4.7B | ||
| Q2 25 | $81.2M | $4.5B | ||
| Q1 25 | $85.0M | $4.5B | ||
| Q4 24 | $80.2M | $4.8B | ||
| Q3 24 | $64.0M | $4.8B | ||
| Q2 24 | $65.2M | $4.8B | ||
| Q1 24 | $66.6M | $5.3B |
| Q4 25 | 0.79× | — | ||
| Q3 25 | 0.97× | — | ||
| Q2 25 | 1.30× | — | ||
| Q1 25 | 1.16× | — | ||
| Q4 24 | 1.24× | — | ||
| Q3 24 | 1.81× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | 1.13× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $87.0M |
| Free Cash FlowOCF − Capex | — | $78.7M |
| FCF MarginFCF / Revenue | — | 352.4% |
| Capex IntensityCapex / Revenue | — | 37.4% |
| Cash ConversionOCF / Net Profit | — | 5.49× |
| TTM Free Cash FlowTrailing 4 quarters | — | $118.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $87.0M | ||
| Q3 25 | $-2.4M | $26.3M | ||
| Q2 25 | $-942.0K | $44.0M | ||
| Q1 25 | $-2.8M | $-28.7M | ||
| Q4 24 | $2.2M | $133.9M | ||
| Q3 24 | $-1.2M | $169.0M | ||
| Q2 24 | $-5.2M | $45.4M | ||
| Q1 24 | $-5.0M | $-20.4M |
| Q4 25 | — | $78.7M | ||
| Q3 25 | — | $25.9M | ||
| Q2 25 | — | $43.4M | ||
| Q1 25 | — | $-29.6M | ||
| Q4 24 | — | $127.4M | ||
| Q3 24 | — | $166.0M | ||
| Q2 24 | — | $44.9M | ||
| Q1 24 | — | $-21.7M |
| Q4 25 | — | 352.4% | ||
| Q3 25 | — | 93.1% | ||
| Q2 25 | — | 201.6% | ||
| Q1 25 | — | -145.6% | ||
| Q4 24 | — | 468.2% | ||
| Q3 24 | — | 432.1% | ||
| Q2 24 | — | 131.0% | ||
| Q1 24 | — | -58.6% |
| Q4 25 | — | 37.4% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 2.9% | ||
| Q1 25 | — | 4.3% | ||
| Q4 24 | — | 23.9% | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | — | 1.3% | ||
| Q1 24 | — | 3.7% |
| Q4 25 | — | 5.49× | ||
| Q3 25 | — | 1.37× | ||
| Q2 25 | — | 2.57× | ||
| Q1 25 | — | -2.49× | ||
| Q4 24 | 1.46× | 4.27× | ||
| Q3 24 | — | 6.13× | ||
| Q2 24 | — | 1.41× | ||
| Q1 24 | — | -1.24× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
LADR
Segment breakdown not available.
